Tumor necrosis factor-β gene polymorphism may not be associated with major depressive disorder in the Korean population

Psychiatry and Clinical Neurosciences

Volumn 57, Issue 1, 2003, Pages 31-35

  Jun, Tae Youn ^a   Pae, Chi Un ^a   Chae, Jeong Ho ^a   Bahk, Won Myong ^a   Kim, Kwang Soo ^a   Pyo, Chul Woo ^b   Han, Hoon ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Korea; Major depressive disorder; Tumor necrosis factor gene polymorphism

Indexed keywords

LYMPHOTOXIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNE SYSTEM; KOREA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ALLELES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KOREA; LYMPHOTOXIN-ALPHA; MALE; POLYMORPHISM, GENETIC;

EID: 0037326995     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2003.01076.x     Document Type: Article

References (32)

1. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 1999; 4: 317-327.
2. Capuron L, Ravaud A, Gualde N et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001; 26: 797-808.
3. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv. Exp. Med. Biol. 1999; 461: 107-116.
4. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996; 711: 163-174.
5. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J. Psychosom. Res. 1997; 43: 529-534.
6. Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr. Scand. 1991; 84: 379-386.
7. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol. Psychiatry 1994; 35: 42-47.
8. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001; 11: 203-208.
9. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
10. Kagaya A, Kugaya A, Takebayashi M et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001; 43: 59-62.
11. Maes M, Song C, Lin AH et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-379.
12. Yirmiya R, Pollak Y, Barak O et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001; 24: 531-544.
13. Kanba S, Manki H, Shintani F, Ohno Y, Yagi G, Asai M. Aberrant interleukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode. Psychol. Med. 1998; 28: 481-484.
14. Mössner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem. Int. 1998; 33: 251-254.
15. Mössner R, Daniel S, Schmitt A, Albert D, Lesch KP. Modulation of serotonin transporter function by interleukin-4. Life Sci. 2001; 68: 873-880.
16. Du L, Bakish D, Hrdina PD. Tryptophan hydroxylase gene 218A/C polymorphism is associated with somatic anxiety in major depressive disorder. J. Affect. Disord 2001; 65: 37-44.
17. Arias B, Gutierrez B, Pintor L, Gasto C, Fananas L. Variability in the 5-HT (2A) receptor gene is associated with seasonal pattern in major depression. Mol. Psychiatry 2001; 6: 239-242.
18. Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ. Association study of the 5-HT (6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001; 44: 172-175.
19. Jun TY, Pae CU, Chae JH, Bahk WM, Kim KS. Polymorphism of CTLA-4 gene for major depression in the Korean population. Psychiatry Clin. Neurosci. 2001; 55: 533-537.
20. Kim TG, Kim HY, Lee SH et al. Systemic lupus erythematosus with nephritis is strongly associated with the TNFB*2 homozygote in the Korean population. Hum. Immunol. 1996; 46: 10-17.
21. Messer G, Spengler U, Jung MC et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J. Exp. Med. 1991; 173: 209-219.
22. Schiffer RB, Caine ED. The interaction between depressive affective disorder and neuropsychological test performance in multiple sclerosis patients. J. Neuropsychiatry Clin. Neurosci. 1991; 3: 28-32.
23. Stoll T, Kauer Y, Buchi S, Klaghofer R, Sensky T, Villiger PM. Prediction of depression in systemic lupus erythematosus patients using SF-36 Mental Health scores. Rheumatology 2001; 40: 695-698.
24. Salmaggi A, Palumbo R., Fontanillas L et al. Affective disorders and multiple sclerosis: a controlled study on 65 Italian patients. Ital. J. Neurol. Sci. 1998; 19: 171-175.
25. Keso T, Perola M, Laippala P et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001; 154: 691-697.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, 4th edn. American Psychiatric Press, Washington DC 1994.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated acid. Nucl. Acids Res. 1988; 16: 1215.
28. Cohen J. Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hillsdale, 1988.
29. Yamaguchi E, Itoh A, Hizawa N, Kawakami Y. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest 2001; 119: 753-761.
30. Whichelow CE, Hitman GA, Raafat I, Bottazzo GF, Sachs JA. The effect of TNF*B gene polymorphism on TNF-alpha and -beta secretion levels in patients with insulin-dependent diabetes mellitus and healthy controls. Eur. J. Immunogenet. 1996; 23: 425-435.
31. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor-alpha. Clin. Exp. Immunol. 1993; 92: 14q-18.
32. Serretti A, Lilli R, Lorenzi C, Lattuada E, Cusin C, Smeraldi E. Tryptophan hydroxylase gene and major psychoses. Psychiatry Res. 2001; 103: 79-86.